Magnisense won two awards for the MIAG product: Health award “Janus 2018 “and “label 2019 Observer of the design”.

Plastibell

 

MIAG (Mobile Diagnostic), is the first connected mobile device enabling emergency diagnosis of cardiovascular diseases in less than 15 min, from just a few drops of blood, with results being sent to the hospital in real time. Plastibell contributed to the MIAG success and was involved from the design phase, industrialization and is now manufacturing the plastic part of the reagent.

Tekni-Plex acquires cleanroom film extruder, converter Beyers Plastics

Tekni-Plex, Inc. has acquired Beyers Plastics, Puurs, Belgium, a cleanroom Class 7 extruder and converter of polyethylene (PE) film, from investment company FAMO N.V.

Beyers will now become part of Tekni-Plex’s Tekni-Films business unit. It specializes in producing PE packaging for pharmaceutical, medical and other industries such as food, aerospace, solar energy, semi-conductor and chemicals.

“The acquisition of Beyers Plastics allows us to expand our portfolio of cleanroom-produced pharmaceutical and medical flexible packaging products. For the first time, we will have bag converting capability, as well as PE blown film extrusion,” said Joe Horn, senior vice president and general manager, global, Tekni-Films. “The acquisition supports our goal of expanding our offerings in the pharmaceutical and healthcare space.”

“We look forward to becoming part of Tekni-Plex’s global healthcare packaging presence. Our combined expertise and manufacturing capability will provide packaging solutions for more companies, as well as grow sales for our combined product lines,” said Johan Noelmans, general manager, Beyers Plastics.

The Beyers Plastics purchase is the tenth acquisition Tekni-Plex has made in the past four years, supporting its strategy to grow its business though transformative acquisitions and strategic add ons. Tekni-Plex has a solid track record of successful business integrations, having acquired companies with innovative plastic and rubber products to further drive growth.

Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients

Almac Diagnostic Services, a global stratified medicine company specialising in biomarker driven clinical trials, has made a significant investment in a new Illumina NovaSeq 6000 sequencer which will benefit Biopharma clients’ biomarker discovery and clinical trial projects.

The addition of the NovaSeq’s powerful processing capabilities to Almac’s existing range of NGS platform offerings allows for larger sample runs, greater read depth and faster speeds. The new instrument will ultimately reduce sample turnaround times and increase variant detection quality and accuracy for clients.

With the NovaSeq, Almac will be able to sequence the transcriptomes of up to ~384 samples, per run (dual flow cell, 50M reads per sample) in a timeframe as short as 36 hours.  The NovaSeq provides scalable throughput and flexibility for virtually any sequencing method, genome, and scale of project.  To accommodate NovaSeq’s high capacity and efficiency, Almac has also invested in appropriate informatics infrastructure and installed high speed uplinks to cloud based providers.

The NovaSeq will form an integral part of Almac’s current DNA and RNA Sequencing offerings and future offerings for Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES).  Almac Diagnostic Services already has extensive expertise in Next Generation Sequencing (NGS) technology and Bioinformatics. The company offers a customisable solution that allows clients to tailor their diagnostic requirements across multiple platforms and chemistry options to suit their specific translational research or clinical trial needs.

Michael Sloan, Global VP of Commercial Operations, Almac Diagnostic Services said: “We are excited about the potential benefits the NovaSeq will be able to bring to our customers with its sequencing capabilities enhancing our current DNA and RNA NGS panel offerings to the market. We are positioning ourselves at the cutting edge of NGS diagnostics and the investment in this new NGS platform will help Almac to continue to play a leading role within stratified medicine.”

The NovaSeq will also support Almac Diagnostic Services new unique gene expression report, claraT, which will be launched to market at ESMO 2018 in Munich in October. claraT is a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report for cancer research / biomarker discovery.

Series production of Gx RTF ClearJect plastic syringes started

Gerresheimer has commenced with series production of the new Gx RTF ClearJect syringes. The products of the high performance plastic COP (Cyclo Olefin Polymer) are used where especially sophisticated medications need to be packaged. The new Gx RTF ClearJect syringe 1 ml long with cannula is the first plastic syringe developed and produced by Gerresheimer itself.

Gerresheimer brought together its comprehensive competence in glass production at the Bünde location and the expertise of its plastic specialist in the Technical Competence Center (TCC) Wackersdorf for the development and industrialization of the new syringe. The production facility was thus planned and built by the automation team of the Technical Competence Center; the know-how for the quality control and quality guidelines for primary packaging originates from the inspection specialists of the glass location Bünde, and was adapted jointly to the specific requirements of plastic production. Production takes place pursuant to the especially high quality requirements for pharmaceutical primary packaging material corresponding to GMP. The new production facility is conceived in such a way that the entire processing chain from injection molding to finished RTF packaging is covered. A series of cameras were installed at various stations for quality control, with which all relevant geometrical parameters and cosmetic-visual defects are checked for each individual product.

Gerre article

Innovative medications mean strict requirements for their primary packaging. Especially biotechnologically manufactured active agents may not interact with the packaging, because this could mean undesirable effects for patients. Gx RTF ClearJect syringes offer especially low interaction potential. The material COP has a high pH tolerance, does not emit metal ions into the medication solution, and therefore causes no displacement of the pH value while in storage. The syringe is manufactured as an injection molding part in an 8-fold hot runner mold. The cannula is also thereby injected at the same time and does not need to be retroactively glued in. Tungsten and glue residue is therefore eliminated with the Gx RTF ClearJect syringes. The precise geometry of the injection molding part reduces the dead volume in the syringe, leaving behind less of the expensive medication in the syringe. Also attractive is the increased safety for the end consumer. COP is particularly break-resistant, making it suitable for packaging aggressive or toxic materials.

The new Gerresheimer Gx RTF ClearJect COP syringe is available in the long 1 ml size with cannula. The design corresponds to ISO 11040-6. The first version of the syringe is equipped with a 27-gage, 1/2-inch (12.7 mm), and thin-walled stainless-steel needle with three bevels. The syringes are siliconized with a precisely controlled amount of high-viscosity, and thus low-particle Dow Corning 360 MD (12,500 cSt) silicone oil, offering a comprehensive syringe system that completes the COP syringe body with plunger rods, plunger stoppers, finger flange, and closure systems. An economically efficient complete solution is achieved through the use of commercially available standard components.

More information : Syringes made of plastics

Sun Pharma acquires Pola Pharma in Japan, to help in building global dermatology business

Sun Pharmaceutical Industries Ltd. Has announced that Sun Pharma has entered into a definitive agreement to acquire Pola Pharma Inc. (“Pola Pharma”), a Japanese pharmaceutical company engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan. The portfolio of Pola Pharma primarily comprises dermatology products.

Pola Pharma, part of POLA ORBIS Group, has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations.

Kirti Ganorkar, Executive Vice President, Sun Pharma said, “This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us to launch our speciality and generic dermatology products in the Japanese market in future.

We also get access to local manufacturing capability enabling us to serve the Japanese pharmaceutical market more effectively.” Junichi Nakamichi, Country Head of Japan, Sun Pharma said, “By combining Sun Pharma’s global strengths with Pola Pharma’s local expertise, we will have a great opportunity to further strengthen our presence in Japan, especially in the area of dermatology.”

Roche subsidiary Genentech acquires Jecure Therapeutics

Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors.

Genentech has an extensive history of translating pioneering science into transformative medicines,” said Jeffrey A. Stafford, Ph.D., president and CEO of Jecure. “The acquisition of Jecure provides a unique opportunity to bring novel NLRP3 inhibitors to patients.

“We’ve had a long-standing interest in targeting inflammatory pathways that may play a role in a number of serious diseases,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “We’re excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with inflammatory diseases.”

Jecure began operations in 2015 with a seed financing from founding investor Versant Ventures. The company raised $20 million in a Series A round from Versant in 2017 to continue to develop and advance its portfolio of NLRP3 inhibitors.